<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01627847</url>
  </required_header>
  <id_info>
    <org_study_id>035-09</org_study_id>
    <nct_id>NCT01627847</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Ropinirole Hydrochloride ER Tablets 2 mg Under Fed Condition</brief_title>
  <official_title>Open Label, Balanced, Randomized, Two-treatment, Two-sequence, Two-period, Single-dose, Crossover Oral Bioequivalence Study of Ropinirole Hydrochloride Extended Release Tablets 2 mg of Dr. Reddy's Laboratories Limited, India With REQUIP@ XL (Ropinirole Hydrochloride Extended Release) 2 mg Tablets of Glaxosmithkline, USA, in Normal, Healthy, Adult, Human Subjects Under Fed Condition.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, randomised, balanced, two-treatment, two-period, two-sequence,
      crossover, oral bioequivalence study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study was to determine the single-dose oral bioequivalence of
      Ropinirole Hydrochloride Extended Release Tablets 2 mg of Dr. Reddy's Laboratories Limited,
      India with REQUIPÂ® XL (Ropinirole Hydrochloride Extended Release) 2 mg Tablets of
      Glaxosmithkline, USA, in normal, healthy, adult, human subjects under fed condition.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under curve(AUC)</measure>
    <time_frame>Pre-dose (before dosing, in the morning of the day of dosing) and at 1.00, 2.00, 3.00,4.00, 5.00, 6.00, 7.00, 8.00, 9.00, 10.00, 11.00, 12.00, 13.00, 14.00, 15.00, 16.00, 17.00, 18.00,20.00, 24.00, 30.00, 36.00, 48.00 and 60.00 hours after dosing.</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Ropinirole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ropinirole Hydrochloride ER tablets 2 mg of Dr. Reddy's Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Requip</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Requip XL Tablets 2 mg of Glaxosmithkline, USA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropinirole</intervention_name>
    <arm_group_label>Ropinirole</arm_group_label>
    <arm_group_label>Requip</arm_group_label>
    <other_name>Requip</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy human subjects aged between 18 and 45 years (including both).

          2. Subjects with a BMI between 18.5 - 24.9 Kg/m2 (including both) but body weight not
             less than 45 Kgs.

          3. Subjects with normal health as determined by personal medical history, clinical
             examination, and laboratory examinations including serological tests.

          4. Subjects having normal 12-lead electrocardiogram (ECG).

          5. Subjects having normal chest X-Ray (PIA view).

          6. Subjects able to communicate effectively.

          7. Subjects willing to give written informed consent and adhere to all the requirements
             of this protocol.

          8. Female subjects who are postmenopausal or surgically sterile.

          9. Female subjects practicing an acceptable method of birth control for the duration of
             the study as judged by the investigator(s), such as condoms, foams, jellies,
             diaphragm,intrauterine device (IUD) or abstinence.

        Exclusion Criteria:

          1. Subjects having contraindications or hypersensitivity to ropinirole or domperidone or
             related group of drugs.

          2. History or presence of any medical condition or disease according to the opinion of
             the physician.

          3. History or presence of significant cardiovascular, pulmonary, hepatic, renal,
             gastrointestinal, endocrine, immunological, dermatological, neurological or
             psychiatric disease or disorder.

          4. History or presence of significant alcoholism or drug abuse in the past one year.

          5. History or presence of significant smoking (more than 10 cigarettes or bidis/day or
             consumption of tobacco products).

          6. Difficulty with donating blood.

          7. Difficulty in swallowing solids like tablets or capsules.

          8. Systolic blood pressure less than 110mm Hg or more than 140 mm Hg.

          9. Diastolic blood pressure less than 70 mm Hg or more than 90 mm Hg.

         10. Pulse rate less than 50 beats/minute or more than 100 beats/minute.

         11. Use of any prescribed medication during last two weeks or OTC medicinal products
             during the last one week preceding the first dosing.

         12. Major illness during 3 months before screening.

         13. Participation in a drug research study within past 3 months.

         14. Donation of blood in the past 3 months before screening.

         15. Female subjects demonstrating a positive pregnancy screen.

         16. Female subjects who are currently breast-feeding.

         17. Female subjects with child bearing potential using prohibited contraceptive method
             (Oral, Injectable or Implantable hormonal agents).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Naba Kr Talukdar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>GVK Biosciences Pvt. Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GVK Biosciences Pvt. Ltd</name>
      <address>
        <city>Ameerpet</city>
        <state>Hyderabad, Andhra Pradesh</state>
        <zip>500 038</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2012</study_first_submitted>
  <study_first_submitted_qc>June 22, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2012</study_first_posted>
  <last_update_submitted>September 27, 2012</last_update_submitted>
  <last_update_submitted_qc>September 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Ropinirole Hydrochloride</keyword>
  <keyword>crossover</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropinirole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

